← GLP-1 receptor agonists × cardiac & vascular function

TrialJACC. Heart failure2025

Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.

Barry A Borlaug et al.PubMed ↗Full text ↗Publisher ↗

A secondary analysis of NCT04788511. The trial’s primary report, PMID 37622681, speaks for it on the map; the numbers here are shown and do not vote.

  • Semaglutidelooks good hereHigher 6-minute walk distance.Randomised, large.

What the trial testedrandomised · 1,145 people · 2025

Randomised vs placebo

Raised 6-minute walk distance

Doesn’t vote: a later paper about the trial

+14.6+8.60 to +20.7

semaglutide vs placebo

As reported

difference 14.6, 95% CI 8.60–20.7

Randomised vs placebo

Raised 6-minute walk distance

Doesn’t vote: a later paper about the trial

+17.1+9.20 to +25.0

semaglutide vs placebo

As reported

difference 17.1, 95% CI 9.20–25.0

Who was studied, and how

1,145people with heart failure, in this paper

The trial randomly assignedassigned by chance

semaglutide
placebo

Raised 6-minute walk distance+14.6

randomised

the abstract, start to end

… at 20 weeks (treatment difference 14.6 m [95% CI: 8.6-20.7 m]; P < 0.0001) that was maintained at 52 weeks (treatment difference 17.1 m [95% CI: 9.2-25.0 m]; P < …

← favours treatmentfavours comparator →
could be chance
6-minute walk distance (6MWD)semaglutide vs placebo
14.68.60–20.7
6-minute walk distance (6MWD)semaglutide vs placebo
17.19.20–25.0
GLP-1 receptor agonistsCardiac & vascular function
1 / 4

5 papers cite it

2025
2026
this papercites it

2 trials

NCT04788511phase 3529 enrolled2021a later paper about itNCT04916470phase 3617 enrolled2021
Full record →Abstract, authors, funding and every citing paper · PMID 41045908